Cladribine submission to PBAC – February 2018

1 February 2018

Medication Subsidy (PBAC)
Category
Category
year
Year

MS Australia Submissions

5 May 2025

MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ocrelizumab (Ocrevus®) via subcutaneous (SC) delivery on the Pharmaceutical Benefits Scheme (PBS) for the treatment of people living with relapsing-remitting multiple sclerosis (RRMS).
Medication Subsidy (PBAC)

1 April 2025

MS Australia has undertaken an analysis of the 2025-26 Budget to explore how it will impact the lives of people living with MS.

11 March 2025

MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ublituximab (Briumvi®) on the Pharmaceutical Benefits Scheme (PBS) for the treatment of people living with relapsing remitting multiple sclerosis (MS). 
Medication Subsidy (PBAC)

6 February 2025

MS Australia’s 2025-26 Pre-Budget Submission advocates for strategic investments to support over 33,300 Australians living with MS. Key funding asks include $8M for a National MS Biobank, $300M for a Neurological Research Mission, and $550K for neurological data improvements; $6.5M to expand MS nursing services, a national strategy, and training programs; Improved NDIS pricing, workforce, assistive technology, and income support; and Increased funding for disability-specific aged care services.

13 December 2024

MS Australia’s submission on the second round of NDIS Act amendments supports enhanced statutory duties for providers and key personnel, emphasising accountability and the need for guidance, training, and clarity. It endorses stronger penalties but urges proportionality and clear definitions. Anti-promotion orders, expanded banning categories, and data storage rules are welcomed with caveats. The recommendations focus on balancing safeguarding participants with practical provider considerations.
Disability, NDIS
Read More

Newsletter subscription

  • Enter your details

Cladribine submission to PBAC – February 2018